Searched for: school:SOM
Department/Unit:Neurology
Examination of plasma biomarkers of amyloid, tau, neurodegeneration, and neuroinflammation in former elite American football players
Miner, Annalise E; Groh, Jenna R; Tripodis, Yorghos; Adler, Charles H; Balcer, Laura J; Bernick, Charles; Zetterberg, Henrik; Blennow, Kaj; Peskind, Elaine; Ashton, Nicholas J; Gaudet, Charles E; Martin, Brett; Palmisano, Joseph N; Banks, Sarah J; Barr, William B; Wethe, Jennifer V; Cantu, Robert C; Dodick, David W; Katz, Douglas I; Mez, Jesse; van Amerongen, Suzan; Cummings, Jeffrey L; Shenton, Martha E; Reiman, Eric M; Stern, Robert A; Alosco, Michael L; ,
INTRODUCTION/BACKGROUND:Blood-based biomarkers offer a promising approach for the detection of neuropathologies from repetitive head impacts (RHI). We evaluated plasma biomarkers of amyloid, tau, neurodegeneration, and inflammation in former football players. METHODS:The sample included 180 former football players and 60 asymptomatic, unexposed male participants (aged 45-74). Plasma assays were conducted for beta-amyloid (Aβ) 40, Aβ42, hyper-phosphorylated tau (p-tau) 181+231, total tau (t-tau), neurofilament light (NfL), glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), Aβ42/p-tau181 and Aβ42/Aβ40 ratios. We evaluated their ability to differentiate the groups and associations with RHI proxies and traumatic encephalopathy syndrome (TES). RESULTS:= 0.008). DISCUSSION/CONCLUSIONS:Plasma p-tau181 and p-tau231, GFAP, and NfL may offer some usefulness for the characterization of RHI-related neuropathologies. HIGHLIGHTS/CONCLUSIONS:Former football players had higher plasma p-tau181 and p-tau231 and lower Aβ42/ptau-181 compared to asymptomatic, unexposed men. Younger age of first exposure was associated with increased plasma NfL and GFAP in older but not younger participants. Plasma GFAP was higher in participants with TES-CTE possible/probable compared to TES-CTE no/suggestive.
PMCID:11567811
PMID: 39351900
ISSN: 1552-5279
CID: 5751932
Lessons Learned From Extracorporeal Life Support Practice and Outcomes During the COVID-19 Pandemic
Gill, George; O'Connor, Michael; Nunnally, Mark E; Combes, Alain; Harper, Michael; Baran, David; Avila, Mary; Pisani, Barbara; Copeland, Hannah; Nurok, Michael
Extracorporeal membrane oxygenation is increasingly being used to support patients with hypoxemic respiratory failure and cardiogenic shock. During the COVID-19 pandemic, consensus guidance recommended extracorporeal life support for patients with COVID-19-related cardiopulmonary disease refractory to optimal conventional therapy, prompting a substantial expansion in the use of this support modality. Extracorporeal membrane oxygenation was particularly integral to the bridging of COVID-19 patients to heart or lung transplantation. Limited human and physical resources precluded widespread utilization of mechanical support during the COVID-19 pandemic, necessitating careful patient selection and optimal management by expert healthcare teams for judicious extracorporeal membrane oxygenation use. This review outlines the evidence supporting the use of extracorporeal life support in COVID-19, describes the practice and outcomes of extracorporeal membrane oxygenation for COVID-19-related respiratory failure and cardiogenic shock, and proposes lessons learned for the implementation of extracorporeal membrane oxygenation as a bridge to transplantation in future public health emergencies.
PMID: 39469754
ISSN: 1399-0012
CID: 5746842
Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab [Case Report]
Gibson, Alec W; Elser, Holly; Rosso, Michela; Cornblath, Eli J; Fonkeu, Yombe; Prasad, Sashank; Rothstein, Aaron; Nasrallah, Ilya M; Wolk, David A; Guo, Michael H
INTRODUCTION/BACKGROUND:Anti-amyloid antibody therapies such as lecanemab are increasingly being used to treat Alzheimer's disease (AD). These therapies are associated with a high rate of amyloid-related imaging abnormalities (ARIA). METHODS:We review the case history of a patient who developed ARIA associated with lecanemab treatment. RESULTS:In addition to microhemorrhages and cerebral edema that are recognized features of ARIA, the patient developed several ischemic strokes. The patient also experienced frequent electrographic seizures without overt clinical seizures. The patient demonstrated clinical and radiographic improvement after steroid treatment. DISCUSSION/CONCLUSIONS:Our case suggests that ischemic strokes may be a feature of ARIA and highlights the importance of having a high clinical suspicion for seizures in ARIA. As anti-amyloid therapies are likely going to be increasingly used to treat AD, it is important to appreciate the spectrum of clinical and radiographic findings that can result as side effects from this class of therapies. HIGHLIGHTS/CONCLUSIONS:We report a patient who developed severe amyloid-related imaging abnormalities (ARIA) after treatment with lecanemab. Our report suggests that ischemic strokes may be a novel imaging feature of ARIA. Our report highlights the need for high clinical suspicion for seizures in ARIA.
PMCID:11567816
PMID: 39215494
ISSN: 1552-5279
CID: 5806102
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, Howard H; Cummings, Jeffrey L; Boxer, Adam L; Staffaroni, Adam M; Knopman, David S; Sukoff Rizzo, Stacey J; Territo, Paul R; Arnold, Steven E; Ballard, Clive; Beher, Dirk; Boeve, Bradley F; Dacks, Penny A; Diaz, Kristophe; Ewen, Colin; Fiske, Brian; Gonzalez, M Isabel; Harris, Glenn A; Hoffman, Beth J; Martinez, Terina N; McDade, Eric; Nisenbaum, Laura K; Palma, Jose-Alberto; Quintana, Melanie; Rabinovici, Gil D; Rohrer, Jonathan D; Rosen, Howard J; Troyer, Matthew D; Kim, Doo Yeon; Tanzi, Rudolph E; Zetterberg, Henrik; Ziogas, Nick K; May, Patrick C; Rommel, Amy
The tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for primary tauopathies. In this context, designing the most efficient development programs to translate promising targets and treatments from preclinical studies to early-phase clinical trials is vital. In September 2022, the Rainwater Charitable Foundation convened an international expert workshop focused on the translation of tauopathy therapeutics through early-phase trials. Our report on the workshop recommends a framework for principled drug development and a companion lexicon to facilitate communication focusing on reproducibility and achieving common elements. Topics include the selection of targets, drugs, biomarkers, participants, and study designs. The maturation of pharmacodynamic biomarkers to demonstrate target engagement and surrogate disease biomarkers is a crucial unmet need. HIGHLIGHTS: Experts provided a framework to translate therapeutics (discovery to clinical trials). Experts focused on the "5 Rights" (target, drug, biomarker, participants, trial). Current research on frontotemporal degeneration, progressive supranuclear palsy, and corticobasal syndrome therapeutics includes 32 trials (37% on biologics) Tau therapeutics are being tested in Alzheimer's disease; primary tauopathies have a large unmet need.
PMCID:11567863
PMID: 39316411
ISSN: 1552-5279
CID: 5751892
Trauma and alcohol characteristics related to high intensity binge drinking during college
Edalatian Zakeri, Shiva; Job, Greeshma A; Bing-Canar, Hanaan; Hallihan, Hagar; Paltell, Katherine C; Berenz, Erin C
High intensity (HI) binge drinking has emerged as a high-risk drinking phenotype in young adult drinkers, yet few studies have evaluated clinically meaningful correlates of HI binge drinking among young adults at risk for co-occurring psychopathologies, such as interpersonal trauma-exposed drinkers. The present study compared three groups (i.e., HI binge, standard binge, non-binge drinkers) of interpersonal trauma-exposed college student drinkers (N = 221) on alcohol and interpersonal trauma characteristics. Results of one-way ANOVAs indicated that the HI binge group endorsed significantly greater negative alcohol-related consequences relative to the other two groups. The HI binge group endorsed significantly greater enhancement motives compared to the non-binge group, and no group differences were detected for PTSD and interpersonal trauma characteristics. Individuals who engage in HI binge drinking may experience greater alcohol problems due to their use of alcohol to enhance positive mood. HI binge drinking does not differentiate individuals on the basis of interpersonal trauma experiences or related psychopathology.
PMID: 36084211
ISSN: 1940-3208
CID: 5885832
Alzheimer Disease-Related Biomarkers in Patients on Maintenance Hemodialysis
Masurkar, Arjun V; Bansal, Nisha; Prince, David K; Winkelmayer, Wolfgang C; Ortiz, Daniela F; Ramos, Gianna; Soomro, Qandeel; Vedvyas, Alok; Osorio, Ricardo S; Bernard, Mark A; Debure, Ludovic; Ahmed, Wajiha; Boutajangout, Allal; Wisniewski, Thomas; Charytan, David M
PMCID:11440795
PMID: 39350957
ISSN: 2590-0595
CID: 5703332
A new era of drug discovery for amyotrophic lateral sclerosis
Andrews, Jinsy A
PMID: 39424548
ISSN: 1474-4465
CID: 5873572
Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study Cohort
Chien, Claudia; Cruz E Silva, Vera; Geiter, Emanuel; Meier, Dominik; Zimmermann, Hanna; Bichuetti, Denis B; Idagawa, Marcos I; Altintas, Ayse; Tanriverdi, Uygur; Siritho, Sasitorn; Pandit, Lehka; Dcunha, Anitha; Sá, Maria J; Figueiredo, Rita; Qian, Peiqing; Tongco, Caryl; Lotan, Itay; Khasminsky, Vadim; Hellmann, Mark A; Stiebel-Kalish, Hadas; Rotstein, Dalia L; Waxman, Lindsay; Ontaneda, Daniel; Nakamura, Kunio; Abboud, Hesham; Subei, M Omar; Mao-Draayer, Yang; Havla, Joachim; Asgari, Nasrin; Skejø, Pernille B; Kister, Ilya; Ringelstein, Marius; Broadley, Simon; Arnett, Simon; Marron, Brie; Jolley, Anna M; Wunderlich, Michael; Green, Sean; Cook, Lawrence J; Yeaman, Michael R; Smith, Terry J; Brandt, Alexander U; Wuerfel, Jens; Paul, Friedemann; ,
Background Patients with neuromyelitis optica spectrum disorder (NMOSD) are often seropositive for antibodies against aquaporin-4 (AQP4). The importance of MRI monitoring in this disease requires evaluation. Purpose To profile MRI features from a large international cohort with AQP4 immunoglobulin G (IgG)-seropositive NMOSD (from the Parallel MRI in NMOSD [PAMRINO] study) and to evaluate and confirm existing knowledge regarding the incidence, location, and longitudinal development of characteristic lesions in the central nervous system associated with AQP4-IgG-seropositive NMOSD. Materials and Methods In this retrospective study (from August 2016 to January 2019), MRI and clinical data were collected from 17 NMOSD expert sites in 11 countries across four continents. Clinical features and lesions identified at cross-sectional and longitudinal MRI were assessed. No formal statistical tests were used to compare observations; however, means, SDs, and 95% CIs are reported when evaluating lesion frequencies. Results Available T1-weighted and T2-weighted MRI scans in patients with AQP4-IgG-seropositive NMOSD (n = 525) were read. Among the 525 patients, 320 underwent cerebral MRI examinations with T2-weighted hyperintense cerebral (264 of 320; 82.5%), cerebellar (44 of 320; 13.8%), and brainstem (158 of 321 [49.2%], including one lesion observed at cervical spinal cord [SC] MRI) lesions. Lesions in the optic nerves, analyzed from 152 MRI examinations, were mainly found in the central (81 of 92; 88%) and posterior (79 of 92; 86%) sections (bilaterally in 39 of 92; 42%). Longitudinally extensive transverse myelitis was the predominant SC lesion pattern (upper compartment from 322 MRI examinations, 133 of 210 [63.3%]; and lower compartment from 301 MRI examinations, 149 of 212 [70.3%]). However, nonlongitudinal extensive transverse myelitis lesions were also observed frequently (105 of 210; 50.0%) in the cervical SC. Clinical data (n = 349; mean age, 44 years ± 14 [SD]; 202 female patients) and acute lesions at contrast-enhanced (CE) MRI (n = 58, performed within 30 days of the last attack) were evaluated. CE lesions were detected in the cerebrum (eight of 13; 62%), optic nerves (14 of 19; 74%), or chiasm (three of four; 75%) within 15 days of any relapse. In the upper SC (29 of 44; 66%), CE lesions were frequently observed up to 20 days after a clinical myelitis event. Conclusion A high incidence of abnormal brain MRI examinations and nonlongitudinal extensive SC lesions was found in patients in PAMRINO with AQP4-IgG-seropositive NMOSD. © RSNA, 2024 Supplemental material is available for this article.
PMID: 39530897
ISSN: 1527-1315
CID: 5752832
Migraine and its Association with Stroke in Pregnancy: A National Examination
Reddy, Medha; Vazquez, Sima; Nolan, Bridget; Clare, Kevin; Feldstein, Eric; Medicherla, Chaitanya; Kaur, Gurmeen; Rostanski, Sara K; Czap, Alexandra L; Li, Jin; Gandhi, Chirag D; Al-Mufti, Fawaz
PMID: 39435508
ISSN: 1931-843x
CID: 5739702
Implementing an accelerated three-year MD curriculum at NYU Grossman School of Medicine
Cangiarella, Joan; Rosenfeld, Mel; Poles, Michael; Webster, Tyler; Schaye, Verity; Ruggles, Kelly; Dinsell, Victoria; Triola, Marc M; Gillespie, Colleen; Grossman, Robert I; Abramson, Steven B
Over the last decade there has been tremendous growth in the development of accelerated MD pathways that allow medical students to graduate in three years. Developing an accelerated pathway program requires commitment from students and faculty with intensive re-thinking and altering of the curriculum to ensure adequate content to achieve competency in an accelerated timeline. A re-visioning of assessment and advising must follow and the application of AI and new technologies can be added to support teaching and learning. We describe the curricular revision to an accelerated pathway at NYU Grossman School of Medicine highlighting our thought process, conceptual framework, assessment methods and outcomes over the last ten years.
PMID: 39480996
ISSN: 1466-187x
CID: 5747302